article thumbnail

Targeting HER3 – a little wave of drug development that’s about to get a lot bigger

SugarCone Biotech

Reporting in Nature Reviews Drug Discovery, @AsherMullard noted that Merus must provide the FDA with confirmatory evidence of benefit in both NSCLC and pancreatic adenocarcinoma in order to achieve full approval and that analysts predict annual sales of around $180 million by 2030 per consensus forecast via Cortellis.

article thumbnail

Overcome fear and the myths of Artificial Intelligence

Perficient: Drug Development

Furthermore, platforms offer different payment schemes for licensing and use. Acquiring AI Solutions is very expensive There is a wide variety of AI tool offerings on the market, which allows for greater price competitiveness. Likewise, today, there are applications whose free version allows us to experiment with AI.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

Naturally many of these acquisitions are driven by enthusiasm for clinical-stage assets that may contribute meaningfully to revenues in 2030+, and we are seeing Pharma build deeply in several key areas (obesity, immunology, oncology, neuro) as they add on to existing franchises or build new ones. Join the club.

article thumbnail

ViiV?Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool

The Pharma Data

ViiV Healthcare and MPP are actively negotiating voluntary licensing terms to help widen access to innovative HIV prevention measure . Widening access for an injectable such as this is complex and will take all stakeholders playing their part.

article thumbnail

Identify and Validate Innovative Peptides for the Treatment of Obesity

The Pharma Data

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. ii It is projected that by 2030, close to half of the U.S. NASH and type 2 diabetes, as well as for a number of cancers.

article thumbnail

BioArctic receives European patent for new antibodies targeting Alzheimer’s disease

The Pharma Data

The patent enters into force on 27 January 2021 and expires in 2030. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. and are linked to the company’s project AD1503.

article thumbnail

Bayer to launch Vynyty Citrus®, its newest biological product to control citrus farm pests during virtual symposium

The Pharma Data

It is licensed for commercial use by Ecología y Protección Agricola (EPA) in Valencia and provides 400 days of pest control. This biological solution responds to Bayer’s commitment to help reduce the environmental impact of crop protection by 30% by 2030 without reducing crop yields.